RxDoctor Payments Data

Colleen Erb

Acute Care · Philadelphia, PANPI 1770795031

Payments from drug & device makers

$431in general payments, 2019–2025

Across 13 payments — averaging $33.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$122
  • Johnson & Johnson$97
  • Gilead$91
  • Hologic Sales And Service, LLC$30
  • Takeda Pharmaceuticals U.S.A., Inc.$29
  • AbbVie$28
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$33277%
  • Education$9923%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$431 in reported general payments places this provider in the 60th percentile of 872 acute care providers in Pennsylvania.

See all acute care providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$40,450
Medicare patients
221
Services billed
506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib52$871,071
RevlimidLenalidomide41$748,352
Lenalidomide33$472,497
JakafiRuxolitinib Phosphate16$320,577
IbrancePalbociclib19$298,814
BrukinsaZanubrutinib24$293,561
AlecensaAlectinib Hcl12$222,244
EliquisApixaban57$53,448
CreonLipase/Protease/Amylase22$50,630
Imatinib Mesylate12$16,041
ValacyclovirValacyclovir Hcl45$2,617
Sucralfate12$1,872
Hydroxyurea41$1,178
Prednisone18$897
Anastrozole26$875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$122$320,57716 claims
AbbVieCreon$28$50,63022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 872 acute care providers in Pennsylvania.

Other acute care in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →